9th Annual Biomarkers Congress
Inaugural HDAC inhibitors: Meeting the Challenges of Chemical Development of HDAC Inhibitors Oct (16 -17)
World Trade Center
200 Seaport Boulevard
Boston, MA
http://www.discoveryontarget.com/07hdc.asp
Inaugural HDAC inhibitors: Meeting the Challenges of Chemical Development of HDAC Inhibitors 
Cambridge Healthtech Institute
World Trade Center
Boston


Schedule of Presentations:

Tuesday, October 16, 2007
07:30:00 Registration & Morning Coffee (07:30-08:30)
08:30:00 OVERCOMING THE CHALLENGES: ADVANCED HDAC INHIBITORS (08:30-11:10) Robert Martell, Mitchell Keegan, Henri Lichenstein, Thomas A. Miller, Paul A. Marks
08:30:00 OVERCOMING THE CHALLENGES - ADVANCED HDAC INHIBITORS: Chairperson’s Remarks (08:30-08:40) Paul A. Marks
08:40:00 OVERCOMING THE CHALLENGES - ADVANCED HDAC INHIBITORS: Histone Deacetylase Inhibitors: Bench to Bedside (08:40-09:10) Thomas A. Miller
09:10:00 OVERCOMING THE CHALLENGES - ADVANCED HDAC INHIBITORS: Romidepsin: Maximizing the Potential of a Novel HDAC Inhibitor (09:10-09:40) Mitchell Keegan
09:40:00 OVERCOMING THE CHALLENGES - ADVANCED HDAC INHIBITORS: MGCD0103, A Novel HDAC Inhibitor: From Bench to Clinic (09:40-10:10) Robert Martell
10:10:00 OVERCOMING THE CHALLENGES - ADVANCED HDAC INHIBITORS: MGCD0103, A Novel HDAC Inhibitor: Grand Opening Coffee Break in the Exhibit Hall (10:10-10:30)
10:30:00 OVERCOMING THE CHALLENGES - ADVANCED HDAC INHIBITORS: Belinostat: A pan-HDAC Inhibitor for Treatment of Solid and Hematologic Cancers (10:30-11:10) Henri Lichenstein
11:10:00 MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Histone Deacetylase Inhibitors: Molecular Mechanism of Action (11:10-11:40) Paul A. Marks
11:10:00 MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT(11:10-16:30) Howard Scher, Madeleine Duvic, Thomas Beckers, Steven Grant, Pamela N. Munster, Peter Ordentlich, Sriram Balasubramanian, Paul A. Marks
11:40:00 MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Development of Biomarkers for Clinical Advancement of Broad-Spectrum and Isoform-Selective HDAC Inhibitors (11:40-12:10) Sriram Balasubramanian
12:10:00 MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Pharmacological Properties and Biomarker Strategies for the Development of 2nd Generation HDAC Inhibitors (12:10-12:40) Thomas Beckers
12:40:00 MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Technology Watch - SNDX-275, an orally active class 1 specific histone deacetylase inhibitor with tumor modifying properties (12:40-12:55) Peter Ordentlich
12:55:00 MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Lunch on your own (12:55-13:10)
13:10:00 MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Session Break (13:10-14:20)
13:10:00 MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Panel Chairperson’s Remarks (13:10-14:20) Paul A. Marks
14:25:00 MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Panel Discussion- Are HDAC Inhibitors Proving Their Worth in the Clinic? (14:25-15:25) Steven Grant, Howard Scher, Madeleine Duvic, Pamela N. Munster, Paul A. Marks
15:25:00 Rational Strategies Combining HDAC Inhibitors with other Targeted Agents (15:25-15:55) Steven Grant
15:55:00 Networking Refreshment Break in the Exhibit Hall (15:55-16:30)
16:30:00 TARGETING NOVEL INDICATIONS (16:30-19:30) Holger Patzke, Jeffrey Besterman, Pamela N. Munster
16:30:00 TARGETING NOVEL INDICATIONS: The Power of HDAC Inhibitors: From Oncology to Non-Oncology Indications (16:30-17:00) Jeffrey Besterman
17:00:00 TARGETING NOVEL INDICATIONS: Combination HDAC Therapies in Solid Tumors (17:00-17:30) Pamela N. Munster
17:30:00 TARGETING NOVEL INDICATIONS: Development of HDAC Inhibitors for CNS Indications (17:30-18:00) Holger Patzke
18:00:00 TARGETING NOVEL INDICATIONS: Happy Hour in the Exhibit Hall (18:00-19:30)
19:30:00 End of Conference Day
Wednesday, October 17, 2007
07:30:00 Roundtable Discussion Sessions - Topic: HDAC Inhibitors and Cardiac Safety (07:30-08:30)
07:30:00 Registration, Morning Coffee & Roundtable Discussion Sessions (07:30-08:30)
08:30:00 Keynote Introduction (08:30-08:40)
08:40:00 Keynote Session: Executive Panel: Delivering Drugs for Difficult Targets(08:40-09:40) Lex Van der Ploeg, Jesus Tito Gonzalez, John J. Rossi, Mikael Dolsten, Shama Kajiji, Alexander Rod MacKenzie
09:40:00 Networking Coffee Break in the Exhibit Hall (09:40-10:35)
10:35:00 NEXT GENERATION HDAC INHIBITORS (10:35-12:40) Thomas A. Miller, Andreas Schwienhorst, Andrea Carfi, Graham Packham, Janine Arts
10:35:00 NEXT GENERATION HDAC INHIBITORS: Chairperson’s Remarks (10:35-10:40) Thomas A. Miller
10:40:00 NEXT GENERATION HDAC INHIBITORS: Substrate and Inhibitor Specificities of HDACs Lessons to Learn From a Bacterial Class 2 Homologue (10:40-11:10) Andreas Schwienhorst
11:10:00 NEXT GENERATION HDAC INHIBITORS: Structural Biology of Human Histone Deacetylase Enzymes (11:10-11:40) Andrea Carfi
11:40:00 NEXT GENERATION HDAC INHIBITORS: Improving on Nature: Optimized HDAC Inhibitors Based on Synthetic Depsipeptides (11:40-12:10) Graham Packham
12:00:00 Roundtable Discussion Sessions - Topic: HDAC Inhibitors and Drug Selectivity Issues (07:30-08:30) Thomas A. Miller
12:10:00 NEXT GENERATION HDAC INHIBITORS: JNJ-26481585 - A Novel “Second-generation” Oral Pan-Histone Deacetylase (HDAC) Inhibitor - Shows Broad-spectrum Preclinical Antitumoral Activity Against Solid and Haematological Malignancies (12:10-12:40) Janine Arts
12:40:00 Close of HDAC Inhibitors Conference
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.